Protein behind insulins effectiveness in controlling glucose uptake uncoveredNovember 6th, 2008 - 1:30 pm ICT by ANI
Washington, November 6 (ANI): A PhD student at Sydney’’s Garvan Institute of Medical Research has made a significant advance towards understanding exactly how insulin prompts fat and muscle cells to absorb glucose, a problem that has puzzled researchers for over 50 years.
“Since the 1920s, when Banting and Best discovered insulin, scientists have been battling to discover how it actually works,” said Professor David James, head of Garvan’’s Diabetes Program.
“Then along comes Freddy Yip, doing his PhD, who unveils a completely novel action of insulin, one which we believe plays a fundamental role in glucose uptake, a process that is defective in Type 2 diabetes,” he added.
Type 2 diabetes involves two processesinsufficient production of insulin in the pancreas after a meal, and faulty uptake and storage of glucose in fat and muscle cells, or ”insulin resistance”.
It is on the intersection between the two processes that Freddys finding focuses on.
“In the cell we have series of motor proteins that have the ability to move other molecules from one place to another along intracellular rail road tracks,” he said.
“I have discovered that insulin activates a specific kind of motor protein known as Myo1c, which in turn performs a critical role in glucose uptake,” he added.
Insulin controls glucose uptake into fat cells by moving glucose transporter proteins from inside the cell to the surface membrane, in order that they can pump glucose into the cell. Myo1c aids in the process by helping the transporters slide into the surface membrane.
Among people with good health, around 80 per cent of the glucose transporters migrate to the cell membrane after a meal, allowing plenty of glucose into the cell. However, in Type 2 diabetics, the figure drops to around 10 per cent.
Freddy believes that his work will create a strong foundation for future diabetes research.
“We knew before that Myo1c was somehow involved in the regulation of glucose transport. My research indicates that Myo1c is a major target of insulin action and helps to accelerate the delivery of transporters to the membrane,” he said.
“We think there may be blockages in the signal between insulin and myo1c in people who develop insulin resistance. If we”re correct, it should be possible to target that pathway for development of new therapies,” he added.
Professor James hailed Freddys work by saying: “While we”re certainly not saying we”ve found a way to cure diabetes, we are saying we”ve found a pretty significant clue.”
The study has been reported in the online edition of the journal Cell Metabolism. (ANI)
- Potential new non-insulin treatment for type 1 diabetes found - Mar 25, 2011
- Micro-RNA that regulates insulin in obesity identified - Apr 01, 2011
- Role of motor protein in hearing loss revealed - Mar 07, 2011
- Pair of liver molecules could control diabetes - Apr 09, 2012
- Protein study sheds light on insulin response and cancer cell growth - Nov 06, 2010
- High-fat diet lowers blood sugar in diabetics - May 13, 2012
- Biochemical to treat diabetes discovered - Jul 16, 2012
- Ginger could help control diabetes - Aug 07, 2012
- Brain protein shows promise in checking obesity - Aug 10, 2011
- Link between high-fat diets, type 2 diabetes clarified - Apr 12, 2011
- Insulin-releasing switch found - Mar 16, 2011
- Diabetes in your genes makes obesity inevitable - May 11, 2010
- Scientists discover a new way insulin-producing cells die - Feb 27, 2011
- High fructose levels make maturing fat cells fatter, less insulin-sensitive - Jun 22, 2010
- Brain molecule may play key role in obesity and diabetes - Apr 20, 2011
Tags: action of insulin, banting, cell membrane, diabetes program, diabetes research, fat cells, fundamental role, garvan institute of medical research, glucose transporter, glucose uptake, insulin controls, insulin resistance, insulins, motor protein, motor proteins, muscle cells, production of insulin, surface membrane, transporter proteins, type 2 diabetes